{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for amphotericin root_notes_note in Note (approximate match)
Status:
Possibly Marketed Outside US
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
Butirosin by SigmaAldrich
Source URL:
Class:
MIXTURE
Butirosin is water-soluble aminoglycosidic antibiotic complex which is active against both Gram-positive and Gram-negative bacteria. Butirosin is less toxic than neomycin and shows a good antibacterial activity, including Pseudomonas aeruginosa, which is resistant to neomycin, ribostamycin and kanamycin.
Status:
US Approved Rx
(2007)
First approved in 2003
Class:
PROTEIN
Status:
US Approved Rx
(2005)
First approved in 2002
Source:
BLA103666
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
Vaccine. Mar 2006;24(10):1726-33.: Phase 2 Human clinical trial Completed N/A
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02888106: Phase 2 Interventional Completed Chronic Viral Hepatitis B With Delta-agent
(2016)
Source URL:
Class:
PROTEIN
HBVPRES/2-48CONS-MYR (known as Bulevirtide or Myrcludex B) was developed as an agent bind and inactivate the hepatocyte surface protein sodium taurocholate cotransporting polypeptide (SLC10A1 or NTCP). By blocking NTCP, the drug misdirects hepatitis B virus (HBV) and co-infecting hepatitis D virus (HDV) to an unproductive pathway and thereby prevents infection of the cell. Because NTCP is involved in the bile acid transport cycle, the blockade of this target by myrcludex B can potentially be used for the treatment of various metabolic and inflammatory diseases. Myrcludex B is going to participate in phase 3 trial for patients with chronic hepatitis D, however, the study is not yet recruited. The drug successfully completed phase II clinical trial for the patients with chronic hepatitis B and D. In addition, myrcludex B has been studied during preclinical research as a potential treatment of dyslipidemias, non-alcoholic steatohepatitis; primary biliary cirrhosis.
Status:
Investigational
Source:
NCT02957266: Phase 3 Interventional Unknown status Cervical Cancer
(2015)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00873756: Phase 1 Interventional Completed Metastatic Colorectal Cancer
(2009)
Source URL:
Class:
PROTEIN
